NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Novo Nordisk (NVO) secured accelerated FDA approval for its GLP-1 drug Wegovy (semaglutide 2.4 mg) to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, marking it as the first GLP-1 therapy approved for this indication. This regulatory milestone, driven by positive ESSENCE study data demonstrating significant improvements in liver fibrosis and steatohepatitis resolution, led to a 2.9% increase in NVO shares upon announcement. The approval expands Wegovy's addressable market beyond obesity and diabetes, reinforcing its position as a primary revenue generator for Novo Nordisk, which saw Wegovy sales reach DKK 36.9 billion in H1 2025, amidst intensifying competition from Eli Lilly in the broader GLP-1 market.

Analysis

Novo Nordisk has secured a significant regulatory win with the FDA's accelerated approval for Wegovy to treat MASH with liver fibrosis, making it the first GLP-1 therapy for this indication. The approval is supported by robust data from the ESSENCE trial, which demonstrated statistically significant improvements in liver fibrosis (36.8% of patients vs. 22.4% on placebo) and resolution of steatohepatitis (62.9% vs. 34.3% on placebo). This expands the addressable market for Wegovy, a key revenue driver that generated DKK 36.9 billion in the first half of 2025, a 78% year-over-year increase. However, this positive development, which prompted a 2.9% share price increase, is set against a backdrop of significant market headwinds. The stock has plunged 39% year-to-date, drastically underperforming its industry, and earnings estimates for 2025 and 2026 have been revised downwards over the past 30 days. While the company's forward P/E of 12.75 is below the industry average, this lower valuation, combined with the share price decline and intense competition from Eli Lilly's products, suggests that investors may have priced in concerns about future growth and market share despite the pipeline advancements.

Key Decisions for Investors

• Investors should weigh the long-term growth potential from Wegovy's expanded MASH indication against the stock's severe 39% year-to-date underperformance and recent downward revisions in 2025 and 2026 earnings estimates.
• The current forward P/E of 12.75, which is below both industry and historical averages, could represent a value opportunity, but warrants caution as it may reflect market concerns over intense competition from Eli Lilly and other emerging players.
• Monitor the regulatory progress of the 25 mg oral semaglutide for obesity, as its potential approval by the end of 2025 could serve as a major catalyst and a critical differentiator in the competitive landscape.